KKR to Acquire Bushu Pharmaceuticals
12.21.22
This is only gets display when printing
Simpson Thacher is representing KKR in connection with its announced acquisition of Bushu Pharmaceuticals Ltd. from BPEA EQT. The transaction is expected to be completed in Q1 2023, subject to regulatory approvals and customary closing conditions.
Bushu Pharma is a leading contract development and manufacturing organization (CDMO) in Japan that manufactures products for worldwide end-markets, with a particular focus on Japan and Asian countries, such as China.
The Simpson Thacher team for the transaction includes Noritaka Kumamoto, Jonathan Stradling, Daisuke Ueta and Yuji Yagi (M&A – Tokyo); Ian Ho (M&A – Hong Kong); and Makiko Harunari and Atsushi Usui (Credit).